Jefferies has started coverage on Insmed (INSM, Financial), assigning it a Buy rating along with a price target of $105. The investment firm highlights Insmed's pioneering status in disease treatment and its robust clinical performance as key factors for a successful rollout of its brensocatib drug. This drug is considered a potential major breakthrough for treating bronchiectasis.
Additionally, Jefferies notes the potential for Insmed's commercial product, Arikayce, to extend its application as a first-line treatment for MAC lung disease. These developments suggest a promising future for Insmed in the healthcare market.
